Cargando…

Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective

Increased understanding of cancer biology, pharmacology and drug delivery has provided a new framework for drug discovery and product development that relies on the unique expression of specific macromolecules (i.e., antigens) on the surface of tumour cells. This has enabled the development of anti-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dahlgren, David, Lennernäs, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356544/ https://www.ncbi.nlm.nih.gov/pubmed/32575828 http://dx.doi.org/10.3390/molecules25122861

Ejemplares similares

Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches
por: Dahlgren, David, et al.
Publicado: (2019)

Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma
por: Khaled, Jaafar, et al.
Publicado: (2022)

Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models
por: Dahlgren, David, et al.
Publicado: (2020)

Drug delivery strategy in hepatocellular carcinoma therapy
por: Yang, Sisi, et al.
Publicado: (2022)

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics
por: Kumari, Mamta, et al.
Publicado: (2023)

Antibody Drug Conjugate Bioinformatics: Drug Delivery through the Letterbox
por: Vlachakis, Dimitrios, et al.
Publicado: (2013)

Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma
por: Ebeling Barbier, Charlotte, et al.
Publicado: (2021)

Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
por: Sheyi, Rotimi, et al.
Publicado: (2022)

The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin
por: Dahlgren, David, et al.
Publicado: (2020)

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
por: Kim, Eunhee G., et al.
Publicado: (2015)

Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies
por: Dahlgren, David, et al.
Publicado: (2021)

Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices
por: Qin, Qiuping, et al.
Publicado: (2022)

A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
por: Kim, Jung Hoon, et al.
Publicado: (2022)

Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats
por: Dahlgren, David, et al.
Publicado: (2021)

Enzyme-Based Labeling Strategies for Antibody–Drug Conjugates and Antibody Mimetics
por: Falck, Georg, et al.
Publicado: (2018)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
por: Wang, Yu-Jie, et al.
Publicado: (2017)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers
por: Peng, Haiyong
Publicado: (2021)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies
por: Galun, Danijel, et al.
Publicado: (2017)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat
por: Dahlgren, David, et al.
Publicado: (2020)

Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment
por: Nader-Marta, Guilherme, et al.
Publicado: (2023)

On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site
por: Vrettos, Eirinaios I, et al.
Publicado: (2018)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates
por: Mou, Si, et al.
Publicado: (2018)

Antibody-drug conjugates: beyond current approvals and potential future strategies
por: Menon, Siddharth, et al.
Publicado: (2022)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Antibody–Drug Conjugates for the Treatment of Acute Pediatric Leukemia
por: Stokke, Jamie L., et al.
Publicado: (2021)

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Prevention of Rat Intestinal Injury with a Drug Combination of Melatonin and Misoprostol
por: Dahlgren, David, et al.
Publicado: (2020)

Recent Advances in the Delivery Carriers and Chemical Conjugation Strategies for Nucleic Acid Drugs
por: Oyama, Shota, et al.
Publicado: (2021)

Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions
por: Yang, Tinglin, et al.
Publicado: (2023)

Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?
por: Liao, Michael Z., et al.
Publicado: (2021)

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
por: Feng, Liang, et al.
Publicado: (2016)

Targeting CD56 with an antibody–drug conjugate in Merkel cell carcinoma
por: Leiendecker, L., et al.
Publicado: (2021)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ub6sgcj63553lumtlnhmqkj64m